Navigation Links
Xenon Receives BIOTECanada Gold Leaf Award
Date:6/17/2008

VANCOUVER, British Columbia, June 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc., a drug discovery and development company, is pleased to announce today that it has been awarded the Promising Early Stage Company of the Year Award by BIOTECanada in the Health category for 2008.

"We are delighted to have received this prestigious award, one of BIOTECanada's four Gold Leaf Awards presented this year," commented Simon Pimstone, Xenon's President and CEO. "This honor is important and made even more so by the fact that it represents recognition by our industry peers of both our achievements to date and the potential that Xenon offers."

"Xenon has made substantial progress in advancing its pipeline of novel compounds acting against targets derived from our clinical genetics approach. In the next 12 months we should have multiple products in clinical development for potential blockbuster markets. Our product pipeline is diverse, and we are excited to be advancing our discoveries into clinical opportunities," Pimstone added.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in pain, lipid modification for treating diabetes/obesity and other diseases, as well as therapies for treating anemia and diseases of iron overload. Xenon has partnerships with Novartis Pharma AG, Roche and Takeda Pharmaceutical Company Ltd. For more information, visit the Company's website at http://www.xenon-pharma.com


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Xenon Announces Appointment of VP, Discovery Research
2. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
3. Advance Nanotechs Owlstone Subsidiary Receives Order From IEE
4. Met-Pro Corporations Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000
5. CryoLifes BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery
6. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
7. Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter
8. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
9. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
10. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
11. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for TenoMend(TM) Collagen Tendon Wrap for the Management and Protection of Tendon Injuries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):